Survodutide Research

Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, Recaldin C et al.

Clinical trial simulations (CTSs) are an increasingly common way to incorporate site staff and participant feedback into clinical trial design. CTSs can help overcome the unique challenges presented in obesity trials. Here, a CTS was conducted for three trials from the SYNCHRONIZE™ phase 3...

Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher-Sørensen J et al.

Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist in clinical development for people with obesity and people with metabolic dysfunction-associated steatohepatitis (MASH). Preclinically, survodutide demonstrated body weight lowering efficacy through decreased energy intake and i...

Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN et al.

The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation o...

Andonie CR, Abusalameh A, Ismail I, Hodrob T, Ladadweh M, Ayesh H et al.

MASLD and its progressive form MASH represent a global public health challenge due to their rising prevalence and their possible progression to cirrhosis and HCC. Resmetirom, dual (e.g., cotadutide, survodutide), and triple GRAs (e.g., retarutide) have demonstrated potential efficacy in recent cl...

Wang B, Huang J, Chen Z

Long F, Challa TD, Efthymiou V, Klug M, Klein T, Neubauer H et al.

Martínez-Castelao A, Górriz JL, Fernández-Fernández B, Soler MJ, Navarro-González JF

Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health issues with high mortality and limited options to prevent end-stage renal failure. Current therapies encompass five classes of drugs: (1) a...

Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN et al.

Obesity has emerged as a pressing global health challenge, and therapies based on glucagon-like Peptide 1 receptor agonists (GLP-1RAs) have transformed its management. Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-labe...

Platz E, Kaplan LM, le Roux CW, Wharton S, Burger S, Hussain SA et al.

Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S et al.

Survodutide is an investigational glucagon receptor/glucagon-like peptide-1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double-blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide ...

van Beek AP

le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S et al.

Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in...

Banerjee M, Pal R, Pal S

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with rising global prevalence, closely linked to type 2 diabetes. While several anti-diabetic agents show promise, a comprehensive analysis comparing their efficacy on biopsy-confirmed histological outcomes, in...

Son JW, le Roux CW, Blüher M, Nauck MA, Lim S

The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel GLP-1-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-enter...

Neff GW

Glucagon is a pancreatic peptide hormone whose receptor (GCGR) is expressed in the liver, kidney, and, to a lesser extent, various other tissues. Glucagon is well known as the counterpart to insulin in glucose homeostasis. However, recent evidence has revealed other potential roles of glucagon, w...

Arun AJ, Darji B, Baig M, Frishman WH, Aronow WS

Cardiovascular disease remains the leading cause of mortality worldwide, with obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH) serving as major upstream drivers. Current therapies largely address downstream risk factors, leaving a need for agents that modify t...

Xiao YJ, Yu S, Zhang YL, Chen J, Liu YQ, Liu XL et al.

This meta-analysis aimed to evaluate the efficacy and safety of survodutide on glycemic control and weight loss in adults.We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy...

Rubio-Herrera MA, Mera-Carreiro S

Obesity is a chronic and relapsing disease associated with medical complications and mortality. Our improved understanding of the relevance of the gut-brain axis in regulating appetite and body weight has encouraged research into nutrient-stimulated gastroenteropancreatic hormones as a new therap...

Mangia A, Valenti LVC

Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, represents one of the leading causes of chronic liver disease worldwide. Its high prevalence is driven by insulin resistance, obesity and type 2 diabetes (T2D) and is associated with cardiovascular disease. The main ...

Stachteas P, Nasoufidou A, Karakasis P, Koiliari M, Karagiannidis E, Koufakis T et al.

The global surge in cardiometabolic diseases, including type 2 diabetes, obesity, and cardiovascular diseases, has reached pandemic levels, demanding bold and innovative solutions. Dual glucagon (Gcg) and glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking advancement in ...